Novel Tetrahydropyran Analogs As Dipeptidyl Peptidase Iv Inhibitors: Profile Of Clinical Candidate (2r,3s,5r)-2-(2,5-Difluorophenyl)-5-[2-(Methylsulfonyl)-2,6-Dihydropyrro Lo[3,4-C]Pyrazol-5(4h)-Yl]Tetrahydro-2h-Pyran-3-Amine (23)

A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate. (C) 2013 Elsevier Ltd. All rights reserved.